Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label trial of cannabidivarin in patients with Rett syndrome

Trial Profile

An open label trial of cannabidivarin in patients with Rett syndrome

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidivarin (Primary)
  • Indications Rett syndrome; Seizures
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 May 2019 Status changed from planning to recruiting, according to a GW Pharmaceuticals media release.
    • 27 Nov 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jan 2019, according to a GW pharmaceuticals media release.
    • 27 Nov 2018 According to a GW pharmaceuticals media release, this trial is due to commence in Q1 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top